Realbotix Reports Financial Results for Q2-2026

About this update from Onco-innovations Ltd.

Realbotix Reports Financial Results for Q2-2026 .bwalignc { text-align: center; list-style-position: inside } .bwblockalignl { margin-left: 0px; margin-right: auto } .bwcellpmargin { margin-bottom: 0px; margin-top: 0px } .bwlistdisc { list-style-type: disc } .bwmarginl2 { margin-left: 60px } .bwpadl0 { padding-left: 0px } .bwtablemarginb { margin-bottom: 10px } .bwuline { text-decoration: underline } .bwvertalignt { vertical-align: top } Realbotix Corp . (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leading developer of humanoid robots and AI systems designed for human interaction across enterprise and consumer environments, reports its interim financial results for the three and six months ended March 31, 2026 (“Q2-2026”). All dollar figures are reported in United States dollars (“USD”), unless otherwise stated. Q2-2026 Financial and Operating Highlights For the three and six months ended March 31, 2026, the Company generated revenue of $225,000 and $578,000, respectively, compared to $727,000 and $1,543,000 for the corresponding periods in the prior fiscal year. The decline in revenue is attributable to a deliberate capital allocation and corporate strategy: The elimination of crypto-staking operations and revenues alongside the wind-down of ancillary crypto operations. The allocation of resources to the AI-integrated humanoid robotics division. The streamlining and repositioning of legacy product offerings to optimize margins. Gross margins for the three and six months ended March 31, 2026, were -1.7% and 19.0%, respectively. This compares to the prior year three and six months of 48.6% and 45.9%. Negative gross margins in the quarter are related to a one-time accounting adjustment of overhead expenses in cost of sales also not present in the prior year’s figures. Operating expenses for the three and six months ended March 31, 2026, were $1,746,000 and $3,423,000, respectively. This compares to the prior year three and six months of $1,318,000 and $3,267,000, respectively. The increase is from the Company scaling its hiring to focus on humanoid robotics and AI product lines and division. Total comprehensive income (loss) for the three and six months ended March 31, 2026, was $442,375 and $(849,000), respectively. This is related to the prior year three and...

View stock analysis, news, and events for Onco-innovations Ltd.